Vanda Q3 net product sales $38.8M, down 41% YoY; generic Hetlioz hurts; two PDUFA dates in H1 2024

Vanda Pharmaceuticals Inc.

2023-Q3 EPS reported $0.09 revenue$147,369,000

Q3 2023 net product sales $38.8M vs $65.3M YoY; net income $0.1M ($0.00 EPS) vs $3.3M ($0.06) prior year.
Hetlioz sales fell 58% to $17.5M due to at-risk generic launch; Fanapt sales $21.3M, down 11%.
FDA accepted sNDAs: Fanapt for bipolar I (PDUFA Apr 2, 2024) and Hetlioz for insomnia (PDUFA Mar 4, 2024).
Tradipitant NDA for gastroparesis ongoing; Phase III motion sickness study over 20% enrolled.
Vanda to file Supreme Court petition by Jan 12, 2024 in Hetlioz ANDA litigation vs Teva/Apotex.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Vanda Pharmaceuticals Inc. reported the third quarter ended September 30, 2023 results: revenue $38.8 million, net income $0.1 million.

Period: the third quarter ended September 30, 2023
Revenue: $38.8 million
Net income: $0.1 million
Result: reported results

Exact text from the filing

Total net product sales from HETLIOZ ® and Fanapt ® were $38.8 million in the third quarter of 2023

View on SEC.gov

Browse all earnings releases →

Vanda Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-037827

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.